ginsenosides + ulinastatin

The combination of ginsenosides and ulinastatin represents a synergistic therapeutic approach primarily used for treating septic acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). This combination has shown significant clinical benefits compared to ulinastatin alone. ## Pharmacological Properties and Mechanisms Ginsenosides are the main effective components of ginseng saponins and are steroid compounds with high anti-tumor, anti-shock, and anti-inflammatory activity that improve and strengthen immunity[1]. They have been shown to inhibit pulmonary inflammation mediated by endotoxins[1]. Ulinastatin is a broad-spectrum protease inhibitor that effectively inhibits the activity of inflammatory factors and reduces their levels, thus playing a role in protecting body organs and systems[3]. It can inhibit a variety of cell proteolytic enzymes, reduce damage of hydrolase to normal tissues, stabilize intracellular lysosomal membranes, and reduce peroxidation reactions by inhibiting peroxide production[3]. When combined, these agents work synergistically to improve several clinical parameters: 1. **Pulmonary vascular permeability**: The combination significantly improves pulmonary capillary permeability index, extravascular lung water index, and oxygenation index compared to ulinastatin alone[1][2]. 2. **Hemodynamics and pulmonary circulation**: Parameters such as cardiac index, intrathoracic blood volume index, and central venous pressure show significant improvement with the combination therapy[1][2]. 3. **Clinical scores**: The ALI score and APACHE II score in patients receiving the combination therapy are significantly lower than those receiving ulinastatin alone[1]. ## Clinical Evidence A randomized clinical trial divided 80 cases of severe sepsis-induced ALI and ARDS into a UTI group and a ginsenosides+UTI group. Both groups received standard care including continuous electrocardiac monitoring, invasive hemodynamic monitoring, ventilator-assisted breathing, circulation support, and anti-infection treatment. The ginsenosides+UTI group received additional ginsenosides treatment for 7 consecutive days[1]. The results showed that the combination therapy significantly improved indicators of pulmonary capillary permeability, pulmonary circulation, blood gases, and hemodynamics compared to ulinastatin alone. The ALI score in the combination group was significantly decreased compared to the ulinastatin group[1]. ## Broader Applications Beyond septic ALI and ARDS, ginsenosides have shown therapeutic potential in various conditions: - Early chronic kidney disease - Non-small-cell lung cancer - Anti-aging effects - Immunoregulation - Neuroregulation - Lipid regulation - Antithrombotic effects - Wound healing[2] The combination of ginsenosides with ulinastatin represents an innovative approach to managing severe inflammatory conditions affecting the lungs, with potential applications in other inflammatory and immune-mediated disorders.

Other names

ginsenosides+UTI group